Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | PKM | P14618 | 2/20 | 0.83 |
| ▸ | DHODH | Q02127 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.67 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.65 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.65 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.63 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MDM4 | O15151 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053873 | 1.00 | MEN1 (0.83) | MEN1KMT2APKMDHODHMAPT | |
| SCHEMBL8439303 | 0.98 | MEN1 (0.80) | MEN1KMT2APKMDHODHMAPT | |
| SCHEMBL15183709 | 0.96 | KMT2A (0.77) | MEN1KMT2APKMDHODHMAPT | |
| SCHEMBL14855554 | 0.96 | KMT2A (0.77) | MEN1KMT2APKMDHODHMAPT | |
| SCHEMBL2028671 | 0.96 | DHODH (0.86) | MEN1KMT2APKMDHODHMAPT | |
| SCHEMBL12700422 | 0.92 | DHODH (0.81) | MEN1KMT2APKMDHODHMAPT | |
| SCHEMBL14855907 | 0.91 | DHODH (0.73) | MEN1KMT2APKMDHODHMAPT | |
| SCHEMBL4670044 | 0.91 | DHODH (0.78) | MEN1KMT2APKMDHODHMAPT | |
| SCHEMBL16404480 | 0.91 | DHODH (0.78) | MEN1KMT2APKMDHODHMAPT | |
| SCHEMBL2029098 | 0.91 | MEN1 (1.00) | MEN1KMT2APKMDHODHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115626879-A | Preparation method of 2-phenylalanyl-benzoic acid derivative | 广州同隽医药科技有限公司 | 2023-01-20 | — | — | CN | claimed |
| CN-109232275-B | Preparation method of 4-nitrodiphenylamine and 4-nitrosodiphenylamine | 科迈化工股份有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-106102477-B | Compositions with reduced bitter taste perception | 宝洁公司 | 2020-03-17 | — | — | CN | claimed |
| EP-2621462-B1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | PROCTER & GAMBLE (US) | 2020-02-12 | — | — | EP | claimed |
| EP-3160592-B1 | COMPOSITIONS WITH REDUCED BITTER TASTE PERCEPTION | PROCTER & GAMBLE (US) | 2018-10-31 | — | — | EP | claimed |
| US-9827320-B2 | Compositions with reduced bitter taste perception | THE PROCTER & GAMBLE COMPANY (US) | 2017-11-28 | — | — | US | claimed |
| EP-3160592-A1 | COMPOSITIONS WITH REDUCED BITTER TASTE PERCEPTION | The Procter & Gamble Company (US) | 2017-05-03 | — | — | EP | claimed |
| CN-102993203-B | The preparations and applicatio of 8-phenyl yanthine analog derivative | WENZHOU MEDICAL COLLEGE (CN) | 2015-11-25 | — | — | CN | claimed |
| WO-2015131001-A1 | COMPOSITIONS WITH REDUCED BITTER TASTE PERCEPTION | THE PROCTER & GAMBLE COMPANY (US) | 2015-09-03 | — | — | WO | claimed |
| US-20150238613-A1 | Compositions With Reduced Bitter Taste Perception | THE PROCTER & GAMBLE COMPANY | 2015-08-27 | — | — | US | claimed |
| EP-2621462-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | claimed |
| CN-102993203-A | Preparation of 8-benzyl xanthine derivative and application | WENZHOU MEDICAL COLLEGE | 2013-03-27 | — | — | CN | claimed |
| WO-2012055170-A1 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES | THE UNIVERSITY OF HONG KONG (CN) | 2012-05-03 | — | — | WO | claimed |
| US-20120107317-A1 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES | THE UNIVERSITY OF HONG KONG (CN) | 2012-05-03 | — | — | US | claimed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | claimed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | claimed |
| EP-0199276-A2 | Process for preparaing substituted 2-phenyl-4H-3,1-benzoxazin-4-ones | BASF Aktiengesellschaft (DE) | 1986-10-29 | — | — | EP | claimed |
| EP-0024669-B1 | SUBSTITUTED N-BENZOYLANTHRANILIC ACID DERIVATIVES AND THEIR ANHYDRO DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS HERBICIDES AND COMPOSITIONS THEREFOR | BASF Aktiengesellschaft (DE) | 1983-04-06 | — | — | EP | claimed |
| US-4235925-A | N-Benzoylanthranilate derivatives as phytopathogenic fungicidal agents | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-11-25 | — | — | US | claimed |
| JP-54002322-A | — | — | None | — | — | JP | disclosed |
| WO-2026087024-A1 | ORAL BIOFILM MODULATION | SYMRISE AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4719062-A2 | METHODS FOR IMPROVING PLANT RESPONSE TO PESTS AND PATHOGENS | Newleaf Symbiotics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025122372-A1 | METHODS FOR AFFECTING PLANT PESTS AND PATHOGENS | NEWLEAF SYMBIOTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| EP-3383502-B1 | ORAL CARE PRODUCT AND METHODS OF USE AND MANUFACTURE THEREOF | COLGATE PALMOLIVE CO (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20250064762-A1 | A SUBSTITUTED AROMATIC DICARBONIC ACID AMIDE AS AN INHIBITOR OF THE FERROPTOSIS SUPPRESSOR PROTEIN-1 (FSP1) | UNIV WUERZBURG J MAXIMILIANS (DE) | 2025-02-27 | — | — | US | disclosed |
| US-20240409939-A1 | COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1 | HOFFMANN-LA ROCHE INC. | 2024-12-12 | — | — | US | disclosed |
| CN-119095603-A | Combinations of oligonucleotides for modulating RTEL1 and FUBP1 | 豪夫迈·罗氏有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| WO-2024243521-A2 | METHODS FOR IMPROVING PLANT RESPONSE TO PESTS AND PATHOGENS | NEWLEAF SYMBIOTICS, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| EP-4456888-A1 | A SUBSTITUTED AROMATIC DICARBONIC ACID AMIDE AS AN INHIBITOR OF THE FERROPTOSIS SUPPRESSOR PROTEIN-1 (FSP1) | Julius-Maximilians-Universität Würzburg (DE) | 2024-11-06 | — | — | EP | disclosed |
| EP-4448106-A1 | COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1 | Hoffmann-La Roche Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240150758-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (US) | 2024-05-09 | — | — | US | disclosed |
| US-11963968-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11852631-B2 | Biomarkers predictive of anti-immune checkpoint response | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-2775839-B1 | METHODS FOR ASSESSING REPELLANT QUALITY OF ORGANIC MATERIALS AND METHODS AND COMPOSITIONS FOR REPELLING ARTHROPODS | UNIV CALIFORNIA (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11834392-B2 | KDM4B inhibitors for the treatment of inflammatory diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834392-B2 | KDM4B inhibitors for the treatment of inflammatory diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-12-05 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230277574-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2023-08-22 | — | — | US | disclosed |
| WO-2023126338-A1 | A SUBSTITUTED AROMATIC DICARBONIC ACID AMIDE AS AN INHIBITOR OF THE FERROPTOSIS SUPPRESSOR PROTEIN-1 (FSP1) | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023111210-A1 | COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1 | F. HOFFMANN-LA ROCHE AG (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230118467-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | SYMRISE AG (DE) | 2023-04-20 | — | — | US | disclosed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | disclosed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | disclosed |
| US-11590152-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-02-28 | — | — | US | disclosed |
| CN-115626879-A | Preparation method of 2-phenylalanyl-benzoic acid derivative | 广州同隽医药科技有限公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | disclosed |
| CN-115103840-A | Substituted thiophenecarboxamides, thiophenecarboxylic acids and derivatives thereof | 拜耳公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220288051-A1 | METHODS FOR TREATING CANCER USING SERIAL ADMINISTRATION OF E3 UBIQUITIN LIGASE DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. | 2022-09-15 | — | — | US | disclosed |
| US-20220281941-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-09-08 | — | — | US | disclosed |
| US-11370823-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220119344-A1 | KDM4B INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT D/B/A ZUCKER INSTITUTE FOR INNOVATION COMMERCIALIZATION | 2022-04-21 | — | — | US | disclosed |
| US-20220031590-A1 | ORAL CARE COMPOSITION | SYMRISE AG (DE) | 2022-02-03 | — | — | US | disclosed |
| CN-113683615-A | Evodiamine derivative and preparation and application thereof | 南华大学 | 2021-11-23 | — | — | CN | disclosed |
| EP-3212773-B1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | disclosed |
| CN-105218386-B | Salts or co-crystals of 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol | 格吕伦塔尔有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-109232275-B | Preparation method of 4-nitrodiphenylamine and 4-nitrosodiphenylamine | 科迈化工股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3800179-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2021-04-07 | — | — | EP | disclosed |
| CN-108135802-B | Oral care compositions and methods of using the same | 高露洁-棕榄公司 | 2021-04-06 | — | — | CN | disclosed |
| WO-2021050832-A2 | METHODS FOR TREATING CANCER USING SERIAL ADMINISTRATION OF E3 UBIQUITIN LIGASE DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210072248-A1 | BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3355849-B1 | ORAL CARE COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS | COLGATE PALMOLIVE CO (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3775208-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| CN-112359018-A | Methods and compositions for regenerating hair cells and/or supporting cells | 麻省眼耳医院 | 2021-02-12 | — | — | CN | disclosed |
| US-20210030775-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2021-02-04 | — | — | US | disclosed |
| US-20210024934-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2021-01-28 | — | — | US | disclosed |
| EP-3533436-B1 | COMPOSITIONS COMPRISING MENTHOL, ISOBORNYL BUTYRATE AND APRITONE | PROCTER & GAMBLE (US) | 2020-12-23 | — | — | EP | disclosed |
| CN-112055749-A | Use of FUBP1 inhibitors for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-12-08 | — | — | CN | disclosed |
| EP-3743057-A1 | TREATMENT OF HEARING LOSS | Massachusetts Eye & Ear Infirmary (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200338160-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-10-29 | — | — | US | disclosed |
| CN-111836802-A | Fungicidal acibenzoates | 拜耳公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-108517022-B | Solid catalyst component for olefin polymerization, catalyst and application thereof | 北京利和知信科技有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-104869987-B | Methods and compositions for regenerating hair cells and/or supporting cells | 麻省眼耳医院 | 2020-10-16 | — | — | CN | disclosed |
| EP-2998001-B1 | COMPOSITION FOR REDUCTION OF TRPA1 AND TRPV1 SENSATIONS | PROCTER & GAMBLE (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3656765-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-27 | — | — | EP | disclosed |
| EP-3653600-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-20 | — | — | EP | disclosed |
| EP-3650439-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-13 | — | — | EP | disclosed |
| EP-3636629-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-04-15 | — | — | EP | disclosed |
| CN-106102477-B | Compositions with reduced bitter taste perception | 宝洁公司 | 2020-03-17 | — | — | CN | disclosed |
| EP-2621462-B1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | PROCTER & GAMBLE (US) | 2020-02-12 | — | — | EP | disclosed |
| CN-110603253-A | Heteroaryl phenylamino quinolines and analogs | 拜耳公司 | 2019-12-20 | — | — | CN | disclosed |
| WO-2019193165-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2019-10-10 | — | — | WO | disclosed |
| EP-2854750-B1 | TRPA1 ANTAGONISTS FOR REDUCING NEGATIVE SENSATIONS CAUSED BY HYDROGEN PEROXIDE | PROCTER & GAMBLE (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3533436-A1 | COMPOSITIONS COMPRISING MENTHOL, ISOBORNYL BUTYRATE AND APRITONE | The Procter & Gamble Company (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2019148067-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019143880-A1 | BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190177308-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. | 2019-06-13 | — | — | US | disclosed |
| EP-2892523-B1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3160592-B1 | COMPOSITIONS WITH REDUCED BITTER TASTE PERCEPTION | PROCTER & GAMBLE (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180280263-A1 | Oral Care Compositions and Methods of Using the Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180273517-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX INC (US) | 2018-09-27 | — | — | US | disclosed |
| EP-3368542-A2 | HIGH INTENSITY SWEETENERS | Senomyx, Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3356356-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3355849-A1 | ORAL CARE COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS | Colgate-Palmolive Company (US) | 2018-08-08 | — | — | EP | disclosed |
| CN-108135802-A | Oral care composition and the method using the composition | 高露洁-棕榄公司 | 2018-06-08 | — | — | CN | disclosed |
| US-9937115-B2 | Oral care compositions with improved flavor | THE PROCTER & GAMBLE COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937115-B2 | Oral care compositions with improved flavor | THE PROCTER & GAMBLE COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937115-B2 | Oral care compositions with improved flavor | THE PROCTER & GAMBLE COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937115-B2 | Oral care compositions with improved flavor | THE PROCTER & GAMBLE COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9932340-B2 | Substituted indoles | ABBVIE INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3287447-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20180052161-A1 | BIOMARKERS FOR MALARIA DIAGNOSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180049960-A1 | Methods And Compositions For Modifying Sensorial Perception | PROCTER & GAMBLE (US) | 2018-02-22 | — | — | US | disclosed |
| US-20170349589-A9 | Substituted Indoles | ABBVIE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9827320-B2 | Compositions with reduced bitter taste perception | THE PROCTER & GAMBLE COMPANY (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170327557-A1 | Efficient delivery of therapeutic molecules to cells of the inner ear | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-16 | — | — | US | disclosed |
| US-9790469-B2 | Established human brown adipocyte line and method for differentiation from an hMADS cell line | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-10-17 | — | — | US | disclosed |
| EP-3212773-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | Massachusetts Eye & Ear Infirmary (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9732071-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| CN-106999973-A | System and method for discharging edible material | 阿甘芳香和精细化工有限公司 | 2017-08-01 | — | — | CN | disclosed |
| US-20170174688-A1 | Substituted Indoles | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170143022-A1 | Compositions Incorporating an Umami Flavor Agent | SENOMYX INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170119032-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED | 2017-05-04 | — | — | US | disclosed |
| WO-2017075257-A2 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-3160592-A1 | COMPOSITIONS WITH REDUCED BITTER TASTE PERCEPTION | The Procter & Gamble Company (US) | 2017-05-03 | — | — | EP | disclosed |
| WO-2017062019-A1 | ORAL CARE COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2017-04-13 | — | — | WO | disclosed |
| US-20170096418-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2017-04-06 | — | — | US | disclosed |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | SENOMYX INC (US) | 2017-03-30 | — | — | US | disclosed |
| EP-3126831-A1 | METHOD FOR SCREENING TRP CHANNELS | The Procter & Gamble Company (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | SENOMYX INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160331659-A1 | Methods And Compositions For Modifying Sensorial Perception | PROCTER & GAMBLE (US) | 2016-11-17 | — | — | US | disclosed |
| US-9491942-B2 | Methods for assessing repellant quality of organic materials and methods and compositions for repelling arthropods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| US-9491942-B2 | Methods for assessing repellant quality of organic materials and methods and compositions for repelling arthropods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2016149386-A1 | BIOMARKERS FOR MALARIA DIAGNOSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2016-09-22 | — | — | WO | disclosed |
| US-9427415-B2 | Methods and compositions for modifying sensorial perception | THE PROCTER & GAMBLE COMPANY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160158136-A1 | COMPOSITION FOR REDUCTION OF TRPA1 AND TRPV1 SENSATIONS | PROCTER & GAMBLE (US) | 2016-06-09 | — | — | US | disclosed |
| WO-2016069906-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2016-05-06 | — | — | WO | disclosed |
| CN-105473554-A | Fused piperidine amides as modulators of ion channels | VERTEX PHARMA | 2016-04-06 | — | — | CN | disclosed |
| EP-2998001-A1 | COMPOSITION FOR REDUCTION OF TRPA1 AND TRPV1 SENSATIONS | The Procter and Gamble Company (US) | 2016-03-23 | — | — | EP | disclosed |
| CN-102993203-B | The preparations and applicatio of 8-phenyl yanthine analog derivative | WENZHOU MEDICAL COLLEGE (CN) | 2015-11-25 | — | — | CN | disclosed |
| WO-2015153184-A1 | METHOD FOR SCREENING TRP CHANNELS | THE PROCTER & GAMBLE COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150272907-A1 | Methods And Compositions For Modifying Sensorial Perception | THE PROCTER & GAMBLE COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-9133142-B2 | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | GRUENENTHAL GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| WO-2015131001-A1 | COMPOSITIONS WITH REDUCED BITTER TASTE PERCEPTION | THE PROCTER & GAMBLE COMPANY (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150238613-A1 | Compositions With Reduced Bitter Taste Perception | THE PROCTER & GAMBLE COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-20150209406-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-30 | — | — | US | disclosed |
| EP-2892523-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | Massachusetts Eye & Ear Infirmary (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-1959915-B1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE AG (DE) | 2015-05-13 | — | — | EP | disclosed |
| EP-2854750-A2 | COMPOSITION FOR REDUCTION OF TRPA1 AND TRPV1 SENSATIONS | The Procter & Gamble Company (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-8911795-B2 | Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching | SYMRISE AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8911795-B2 | Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching | SYMRISE AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140128352-A1 | COMPOUNDS AND METHODS FOR MODULATING MITOCHONDRIAL METABOLISM AND REACTIVE OXYGEN SPECIES PRODUCTION | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128352-A1 | COMPOUNDS AND METHODS FOR MODULATING MITOCHONDRIAL METABOLISM AND REACTIVE OXYGEN SPECIES PRODUCTION | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2014-05-08 | — | — | US | disclosed |
| WO-2014039908-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2013176897-A2 | COMPOSITION FOR REDUCTION OF TRPA1 AND TRPV1 SENSATIONS | THE PROCTER & GAMBLE COMPANY (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130315843-A1 | COMPOSITION FOR REDUCTION OF TRPA1 AND TRPV1 SENSATIONS | THE PROCTER & GAMBLE COMPANY (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| EP-1567143-B1 | ANTHRANILIC ACID AMIDES AND THE DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL AGENTS | SYMRISE AG (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-1567143-B1 | ANTHRANILIC ACID AMIDES AND THE DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL AGENTS | SYMRISE AG (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2621462-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621462-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | disclosed |
| CN-103140209-A | Oral care compositions with improved flavor | PROCTER & GAMBLE | 2013-06-05 | — | — | CN | disclosed |
| EP-2595971-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-8431540-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-8409552-B2 | Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds | SYMRISE AG (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8409552-B2 | Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds | SYMRISE AG (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8409552-B2 | Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds | SYMRISE AG (DE) | 2013-04-02 | — | — | US | disclosed |
| CN-102993203-A | Preparation of 8-benzyl xanthine derivative and application | WENZHOU MEDICAL COLLEGE | 2013-03-27 | — | — | CN | disclosed |
| US-20120315233-A1 | ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS | SYMRISE AG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120315233-A1 | ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS | SYMRISE AG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120315233-A1 | ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS | SYMRISE AG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2012-09-27 | — | — | US | disclosed |
| US-8203016-B2 | Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents | SYMRISE AG (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8203016-B2 | Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents | SYMRISE AG (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8203016-B2 | Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents | SYMRISE AG (DE) | 2012-06-19 | — | — | US | disclosed |
| WO-2012055170-A1 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES | THE UNIVERSITY OF HONG KONG (CN) | 2012-05-03 | — | — | WO | disclosed |
| US-20120107317-A1 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES | THE UNIVERSITY OF HONG KONG (CN) | 2012-05-03 | — | — | US | disclosed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | GRUENENTHAL GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2012010316-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2012-01-26 | — | — | WO | disclosed |
| EP-2405914-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | Omeros Corporation (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | disclosed |
| US-8026272-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2011-09-27 | — | — | US | disclosed |
| EP-2356242-A2 | METHODS FOR USING POSITIVELY AND NEGATIVELY SELECTABLE GENES IN A FILAMENTOUS FUNGAL CELL | Novozymes Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2352831-A1 | METHODS FOR PRODUCING POLYPEPTIDES IN ENZYME-DEFICIENT MUTANTS OF FUSARIUM VENENATUM | Novozymes Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7973163-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110117066-A1 | ESTABLISHED HUMAN BROWN ADIPOCYTE LINE AND METHOD FOR DIFFERENTIATION FROM AN HMADS CELL LINE | UNIVERSITE DE NICE SOPHIA ANTIPOLIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-7943770-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (LV) | 2011-03-24 | — | — | US | disclosed |
| US-20110039808-A1 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor | NOGRA PHARMA LIMITED (IE) | 2011-02-17 | — | — | US | disclosed |
| US-20100261103-A1 | ORGANIC PIGMENT FINE PARTICLES AND METHOD OF PRODUCING THE SAME, PIGMENT-DISPERSION COMPOSITION, PHOTOCURABLE COMPOSITION AND INK-JET INK CONTAINING THE SAME, AND COLOR FILTER USING THE SAME AND METHOD OF PRODUCING THE SAME | FUJIFILM CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S and Wyeth | 2010-09-30 | — | — | US | disclosed |
| US-20100248390-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS | DUKE UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| CN-101842362-A | Benzothiazole compounds | INST MEDICAL W & E HALL | 2010-09-22 | — | — | CN | disclosed |
| WO-2010105103-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2222287-A2 | MULTITARGET COMPOUNDS ACTIVE AT A PPAR AND CANNABINOID RECEPTOR | Giuliani International Limited (IE) | 2010-09-01 | — | — | EP | disclosed |
| US-20100189648-A1 | INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF | HUANG LAN | 2010-07-29 | — | — | US | disclosed |
| US-20100189648-A1 | INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF | HUANG LAN | 2010-07-29 | — | — | US | disclosed |
| EP-1740584-B9 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010039840-A1 | METHODS FOR PRODUCING POLYPEPTIDES IN ENZYME-DEFICIENT MUTANTS OF FUSARIUM VENENATUM | NOVOZYMES, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039889-A2 | METHODS FOR USING POSITIVELY AND NEGATIVELY SELECTABLE GENES IN A FILAMENTOUS FUNGAL CELL | NOVOZYMES, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010009091-A2 | ANTI-INFLAMMATORY AND ANTI-ALLERGY EXTRACTS FROM NETTLE | HERBALSCIENCE GROUP, LLC (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100009927-A1 | Anti-Inflammatory and Anti-Allergy Extracts from Nettle | HERBALSCIENCE GROUP LLC (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090297468-A1 | Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching | SYMRISE GMBH & CO. KG (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090297468-A1 | Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching | SYMRISE GMBH & CO. KG (DE) | 2009-12-03 | — | — | US | disclosed |
| US-7622496-B2 | antiarrhythmia agents; 1-(2-Amino-acetyl)-4-(benzoylamino)-pyrrolidine-2-carboxylic acid; desirable bioavailability properties | ZEALAND PHARMA A/S (DK) | 2009-11-24 | — | — | US | disclosed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090270625-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090264342-A1 | COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| US-20090226537-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226537-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009080821-A2 | RECEPTOR TARGETING LIGANDS | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-07-02 | — | — | WO | disclosed |
| JP-2009107972-A | AMINOBENZALDEHYDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND METHOD FOR PRODUCING AMINOBENZOIC ACID COMPOUND | FUJI CHEM IND CO LTD | 2009-05-21 | — | — | JP | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| EP-2028936-A2 | COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2021331-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-02-11 | — | — | EP | disclosed |
| US-20090035306-A1 | QUINAZOLINONE MODULATORS OF TGR5 | KALYPSYS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2008147826-A1 | MALARIA LIVER STAGE DRUGS | SEATTLE BIOMEDICAL RESEARCH INSTITUTE (US) | 2008-12-04 | — | — | WO | disclosed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1886662-A1 | Anti-microbial compounds for treating bad breath | Symrise GmbH & Co. KG (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1886662-A1 | Anti-microbial compounds for treating bad breath | Symrise GmbH & Co. KG (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-20080008660-A1 | Antimicrobially active compounds for treating bad breath | SYMRISE GMBH & CO. KG (DE) | 2008-01-10 | — | — | US | disclosed |
| US-20080008660-A1 | Antimicrobially active compounds for treating bad breath | SYMRISE GMBH & CO. KG (DE) | 2008-01-10 | — | — | US | disclosed |
| US-20080008660-A1 | Antimicrobially active compounds for treating bad breath | SYMRISE GMBH & CO. KG (DE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007095187-A2 | COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY | TRUSTEES OF BOSTON UNIVERSITY (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | disclosed |
| WO-2007062957-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2007-06-07 | — | — | WO | disclosed |
| US-7186739-B2 | Stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | IMMUPHARMA (FRANCE) SA (FR) | 2007-03-06 | — | — | US | disclosed |
| EP-1740584-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-7060845-B2 | Stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | NEOMPS (FR) | 2006-06-13 | — | — | US | disclosed |
| US-20060089413-A1 | Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents | SYMRISE GMBH & CO. KG (DE) | 2006-04-27 | — | — | US | disclosed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-20050159584-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-07-21 | — | — | US | disclosed |
| US-20050159585-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-07-21 | — | — | US | disclosed |
| EP-1165494-B1 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2003-11-05 | — | — | EP | disclosed |
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| US-20020143191-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | UREKA SARL (FR) | 2002-10-03 | — | — | US | disclosed |
| EP-1165494-A2 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-02 | — | — | EP | disclosed |
| US-6323202-B1 | BENZAMIDE SUBSTITUTES WITH KETONE COMPOUNDS AS ENZYME INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-11-27 | — | — | US | disclosed |
| WO-2000058270-A2 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-10-05 | — | — | WO | disclosed |
| EP-0983226-A1 | NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | MERCK PATENT GmbH (DE) | 2000-03-08 | — | — | EP | disclosed |
| US-5847155-A | Aromatic pyrrolidine amide prolyl endopeptidase inhibitors | PFIZER INC (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998052906-A1 | NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 1998-11-26 | — | — | WO | disclosed |
| EP-0750611-B1 | ANILIDE DERIVATIVES AS FUNGICIDES | AGREVO UK LTD (GB) | 1998-07-08 | — | — | EP | disclosed |
| US-5756524-A | APPLYING TO COMBAT CYTOPATHOGENIC FUNGI | AGREVO UK LIMITED (GB) | 1998-05-26 | — | — | US | disclosed |
| EP-0280367-B1 | Glycine compounds | SHELL INT RESEARCH (NL) | 1993-11-03 | — | — | EP | disclosed |
| EP-0536163-A1 | AROMATIC PYRROLIDINE AND THIAZOLIDINE AMIDES | PFIZER INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| US-5164277-A | Oxyalkylated derivative of ditrimethylolpropane | FUJI PHOTO FILM CO., LTD. (JP) | 1992-11-17 | — | — | US | disclosed |
| CN-1017799-B | GLYCINE COMPOUNDS AND PROCESS FOR PREPARING THEM | SHELL INT RESEARCH (NL) | 1992-08-12 | — | — | CN | disclosed |
| US-5110348-A | Pre-and postemergence | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1992-05-05 | — | — | US | disclosed |
| WO-1991018891-A1 | AROMATIC PYRROLIDINE AND THIAZOLIDINE AMIDES | PFIZER INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0246570-B1 | ZINC AND/OR LEAD SALTS OF CARBOXYLIC ACIDS AND THEIR USE AS ANTICORROSIVES | BASF Lacke + Farben AG (DE) | 1989-09-13 | — | — | EP | disclosed |
| US-4837228-A | HYPOTERMIC AGENTS | THE UNIVERSITY OF MISSISSIPPI (US) | 1989-06-06 | — | — | US | disclosed |
| US-4830775-A | FOR AQUEOUS COATING SYSTEMS | BASF Lacke ± Farben Aktiengesellschaft (DE) | 1989-05-16 | — | — | US | disclosed |
| CN-88100995-A | glycine compound and preparation method thereof | — | 1988-09-07 | — | — | CN | disclosed |
| EP-0280367-A2 | Glycine compounds | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-08-31 | — | — | EP | disclosed |
| EP-0246570-A1 | Zinc and/or lead salts of carboxylic acids and their use as anticorrosives | BASF Lacke + Farben AG (DE) | 1987-11-25 | — | — | EP | disclosed |
| US-4673740-A | Preparation of substituted 2-phenyl-4H-3,1-benzoxazin-4-ones | BASF AKTIENGESELLSCHAFT (DE) | 1987-06-16 | — | — | US | disclosed |
| EP-0199276-A2 | Process for preparaing substituted 2-phenyl-4H-3,1-benzoxazin-4-ones | BASF Aktiengesellschaft (DE) | 1986-10-29 | — | — | EP | disclosed |
| EP-0024669-B1 | SUBSTITUTED N-BENZOYLANTHRANILIC ACID DERIVATIVES AND THEIR ANHYDRO DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS HERBICIDES AND COMPOSITIONS THEREFOR | BASF Aktiengesellschaft (DE) | 1983-04-06 | — | — | EP | disclosed |
| US-4347188-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-08-31 | — | — | US | disclosed |
| US-4347188-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-08-31 | — | — | US | disclosed |
| US-4347188-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-08-31 | — | — | US | disclosed |
| US-4344862-A | Reaction products of sulfonamido-carboxylic acids or carboxamido-carboxylic acids with alkanolamines, and their use as low-foaming corrosion inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1982-08-17 | — | — | US | disclosed |
| US-4321371-A | Substituted N-benzoylanthranilic acid derivatives and their anhydro compounds | BASF AKTIENGESELLSCHAFT (DE) | 1982-03-23 | — | — | US | disclosed |
| US-4321371-A | Substituted N-benzoylanthranilic acid derivatives and their anhydro compounds | BASF AKTIENGESELLSCHAFT (DE) | 1982-03-23 | — | — | US | disclosed |
| US-4321371-A | Substituted N-benzoylanthranilic acid derivatives and their anhydro compounds | BASF AKTIENGESELLSCHAFT (DE) | 1982-03-23 | — | — | US | disclosed |
| US-4315862-A | FROM CITRAL AND A RESORCINOL PERIVATIVE | THE UNIVERSITY OF MISSISSIPPI (US) | 1982-02-16 | — | — | US | disclosed |
| US-4303548-A | Process for coating dispersed minute droplets with membrane | MITSUBISHI PAPER MILLS, LTD. (JP) | 1981-12-01 | — | — | US | disclosed |
| EP-0029529-A1 | Reaction products of sulfone or carboxamido carboxylic acids with alkanol amines, and their use as corrosion inhibitors with low foam formation | BASF Aktiengesellschaft (DE) | 1981-06-03 | — | — | EP | disclosed |
| EP-0024669-A1 | Substituted N-benzoylanthranilic acid derivatives and their anhydro derivatives, process for their preparation, their use as herbicides and compositions therefor | BASF Aktiengesellschaft (DE) | 1981-03-11 | — | — | EP | disclosed |
| EP-0024669-A1 | Substituted N-benzoylanthranilic acid derivatives and their anhydro derivatives, process for their preparation, their use as herbicides and compositions therefor | BASF Aktiengesellschaft (DE) | 1981-03-11 | — | — | EP | disclosed |
| US-4254208-A | DISPERSION, LIQUEFYING, SOLIDS | FUJI PHOTO FILM CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
| US-4235925-A | N-Benzoylanthranilate derivatives as phytopathogenic fungicidal agents | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-11-25 | — | — | US | disclosed |
| US-4235925-A | N-Benzoylanthranilate derivatives as phytopathogenic fungicidal agents | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-11-25 | — | — | US | disclosed |
| US-4235925-A | N-Benzoylanthranilate derivatives as phytopathogenic fungicidal agents | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-11-25 | — | — | US | disclosed |
| US-4230727-A | N-BENZYLIDENEANILINE AND DERIVATIVES | WILLIAM H. RORER, INC. (US) | 1980-10-28 | — | — | US | disclosed |
| US-4187317-A | Sunscreen and erythema treating with N-benzylidene anilenes | WILLIAM H. RORER, INC. (US) | 1980-02-05 | — | — | US | disclosed |
| JP-S542322-A | ALKYL N-ACYLANTHRANYLATE DERIVATIVES, THEIR PREPARATION, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE CONTAINING THE SAME | SUMITOMO CHEM CO LTD | 1979-01-09 | — | — | JP | disclosed |
| JP-S542322-A | ALKYL N-ACYLANTHRANYLATE DERIVATIVES, THEIR PREPARATION, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE CONTAINING THE SAME | SUMITOMO CHEM CO LTD | 1979-01-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370823-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | MEN1 254/4885KMT2A 2721/4885PKM 4849/4885 |
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | MEN1 2758/4885KMT2A 3849/4885PKM 2760/4885 |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | MEN1 718/4885KMT2A 1424/4885PKM 1716/4885 |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | MEN1 2644/4885KMT2A 2697/4885PKM 3251/4885 |
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885PKM 145/4885 |
| US-20090035306-A1 | QUINAZOLINONE MODULATORS OF TGR5 | GRK5, PLAAT5, GPBAR1 | MEN1 4781/4885KMT2A 4183/4885PKM 1804/4885 |
| US-20170119032-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | MEN1 2644/4885KMT2A 2697/4885PKM 3251/4885 |
| US-20050159584-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CPS1, ASNS, ACMSD | MEN1 2985/4885KMT2A 989/4885PKM 3490/4885 |
| US-20170327557-A1 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | MEN1 254/4885KMT2A 2721/4885PKM 4849/4885 |
| US-20240150758-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | FUBP1, FUBP3, SERBP1 | MEN1 4566/4885KMT2A 2708/4885PKM 4329/4885 |
| US-20130315843-A1 | COMPOSITION FOR REDUCTION OF TRPA1 AND TRPV1 SENSATIONS | TRPA1, TRPV1, TRPM2 | MEN1 3192/4885KMT2A 3637/4885PKM 3194/4885 |
| US-20210024934-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | FUBP1, FUBP3, SERBP1 | MEN1 4075/4885KMT2A 2358/4885PKM 4275/4885 |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | MEN1 66/4885KMT2A 1792/4885PKM 4311/4885 |
| US-20220281941-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | HES1, NOTCH1, NOTCH2 | MEN1 254/4885KMT2A 2721/4885PKM 4849/4885 |
| US-20220031590-A1 | ORAL CARE COMPOSITION | TAS2R39, NOX5, F9 | MEN1 3797/4885KMT2A 3006/4885PKM 3212/4885 |
| US-11590152-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | MEN1 66/4885KMT2A 1792/4885PKM 4311/4885 |
| US-20060089413-A1 | Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents | HRH1, CMA1, HRH2 | MEN1 1771/4885KMT2A 1394/4885PKM 1392/4885 |
| US-20050159585-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CPS1, ASNS, ACMSD | MEN1 2985/4885KMT2A 989/4885PKM 3490/4885 |
| US-20150209406-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | MEN1 100/4885KMT2A 4219/4885PKM 4605/4885 |
| US-20090264342-A1 | COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY | ATF1, ATF4, STING1 | MEN1 4138/4885KMT2A 3617/4885PKM 4343/4885 |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | TAS2R5, TAS1R1, TAS2R1 | MEN1 3045/4885KMT2A 2214/4885PKM 1215/4885 |
| US-20170174688-A1 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | MEN1 183/4885KMT2A 64/4885PKM 2686/4885 |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM4, TRPM6 | MEN1 1052/4885KMT2A 3630/4885PKM 1976/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | MEN1 2644/4885KMT2A 2697/4885PKM 3251/4885 |
| US-20020143191-A1 | Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas | CPS1, ACMSD, PROC | MEN1 3133/4885KMT2A 975/4885PKM 3576/4885 |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | FUBP1, FUBP3, SERBP1 | MEN1 4075/4885KMT2A 2358/4885PKM 4275/4885 |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885PKM 145/4885 |
| US-20200338160-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | MEN1 82/4885KMT2A 4253/4885PKM 4618/4885 |
| US-20250064762-A1 | A SUBSTITUTED AROMATIC DICARBONIC ACID AMIDE AS AN INHIBITOR OF THE FERROPTOSIS SUPPRESSOR PROTEIN-1 (FSP1) | AIFM2, SLC40A1, FIP1L1 | MEN1 764/4885KMT2A 3520/4885PKM 2758/4885 |
| US-20210030775-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | MEN1 66/4885KMT2A 1792/4885PKM 4311/4885 |
| US-20090297468-A1 | Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching | H1-0, ASIC1, MCOLN1 | MEN1 594/4885KMT2A 1366/4885PKM 3284/4885 |
| US-20170143022-A1 | Compositions Incorporating an Umami Flavor Agent | TAS2R8, TAS2R45, TAS2R40 | MEN1 2743/4885KMT2A 2393/4885PKM 2081/4885 |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | MEN1 1487/4885KMT2A 352/4885PKM 2979/4885 |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | MEN1 1487/4885KMT2A 352/4885PKM 2979/4885 |
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | HPD, CYP4A22, PAH | MEN1 2409/4885KMT2A 2584/4885PKM 559/4885 |
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | RCC2, EP300, SIGMAR1 | MEN1 3472/4885KMT2A 1150/4885PKM 1792/4885 |
| US-20230277574-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | MEN1 66/4885KMT2A 1792/4885PKM 4311/4885 |
| US-20090226537-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | H1-0, ASIC1, NHERF1 | MEN1 1157/4885KMT2A 1286/4885PKM 4016/4885 |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | BCL2, BAX, BAD | MEN1 4323/4885KMT2A 4047/4885PKM 4036/4885 |
| US-20140128352-A1 | COMPOUNDS AND METHODS FOR MODULATING MITOCHONDRIAL METABOLISM AND REACTIVE OXYGEN SPECIES PRODUCTION | PC, PCK2, TXNRD2 | MEN1 4308/4885KMT2A 4088/4885PKM 227/4885 |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | MEN1 351/4885KMT2A 3554/4885PKM 2630/4885 |
| US-20100189648-A1 | INHIBITORS FOR DISRUPTING THE INTERACTION OF UBIQUITINATION RELATED ENZYMES AND USES THEREOF | MDM2, UBE2N, UBE2E1 | MEN1 3921/4885KMT2A 795/4885PKM 3652/4885 |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | MEN1 254/4885KMT2A 2721/4885PKM 4849/4885 |
| US-20220119344-A1 | KDM4B INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | KDM1B, KDM4B, KDM3B | MEN1 4218/4885KMT2A 31/4885PKM 1261/4885 |
| US-20240409939-A1 | COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1 | FUBP1, TERF2IP, FUBP3 | MEN1 2896/4885KMT2A 2796/4885PKM 4442/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | MEN1 1457/4885KMT2A 347/4885PKM 3007/4885 |
| US-20190177308-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | MEN1 1247/4885KMT2A 4178/4885PKM 1982/4885 |
| US-20180273517-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | MEN1 1247/4885KMT2A 4178/4885PKM 1982/4885 |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | TRPA1, PDE6G, PDE6D | MEN1 404/4885KMT2A 4022/4885PKM 1896/4885 |
| US-20120315233-A1 | ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS | CMA1, TPSAB1, HRH1 | MEN1 1612/4885KMT2A 1414/4885PKM 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.